Generian Pharmaceuticals is developing oral small-molecule medicines for targets often addressed by biologic drugs. Co-founded by University of Pittsburgh researchers Toren Finkel, Bill Chen and Yuan Liu, the company combines expertise in protein regulation and drug discovery to pursue new treatment options. [1]
Its preclinical pipeline includes inhibitors of FcRn, a protein that helps maintain circulating antibodies, for potential use in antibody-mediated autoimmune disease. Generian is also exploring novel therapeutic targets through a research collaboration with Astellas, expanding its search for medicines that can be taken by mouth. [2]